Search - tctmd.com

Displaying 241 - 260 of 724

Sort: Relevancy | Date

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Ticagrelor (PEGASUS Trial)!

Presenter: C. Michael Gibson, Marco Valgimigli, Neal S. Kleiman

October 11, 2015

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Clopidogrel and Prasugrel (DAPT Trial)!

Presenter: C. Michael Gibson, Marco Valgimigli, Robert W. Yeh

October 11, 2015

Presentation TCT 2015

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Prasugrel for Primary PCI Is Simplest and Best!

Presenter: C. Michael Gibson, Marco Valgimigli, Sigmund Silber

October 11, 2015

Presentation TCT 2015

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Oral or Crushed Ticagrelor for All!

Presenter: C. Michael Gibson, Marco Valgimigli, Guido Parodi

October 11, 2015

Presentation TCT 2015

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? The Mechanism and Data Support Cangrelor!

Presenter: C. Michael Gibson, Marco Valgimigli, Harvey D. White

October 11, 2015

Presentation TCT 2015

Case Resolution: How Did We Treat Our STEMI Patient With Multivessel Disease (and What Were the Long-term Outcomes)?

Presenter: Thomas Engstroem, Barry D. Rutherford, Henning Kelbæk

October 11, 2015

Presentation TCT 2015

Case Introduction: A STEMI Patient With Multivessel Disease

Presenter: Thomas Engstroem, Barry D. Rutherford, Henning Kelbæk

October 11, 2015

Presentation TCT 2015

Impact of CTO Revascularization After Primary PCI for AMI: Is This Where the Benefit Lies?

Presenter: Thomas Engstroem, Barry D. Rutherford, David Antoniucci

October 11, 2015

Presentation TCT 2015

Nonculprit Lesions in STEMI Patients With Multivessel Disease: Is the Issue Ischemia or Vulnerable Plaque?

Presenter: Thomas Engstroem, Barry D. Rutherford, David Erlinge

October 11, 2015

Presentation TCT 2015

Should FFR Be Used Routinely in STEMI Patients With Multivessel Disease, and Is It Reliable During the Index and/or Staged Procedures?

Presenter: Thomas Engstroem, Barry D. Rutherford, Colin Berry

October 11, 2015

Presentation TCT 2015

Updated Meta-analysis of Culprit Only vs Complete Revascularization in STEMI: Are We Impacting Death and Reinfarction or Repeat Revascularization Only?

Presenter: Thomas Engstroem, Barry D. Rutherford, Anthony H. Gershlick

October 11, 2015

Presentation TCT 2015

Introduction: A Critical Appraisal of Culprit Only vs Multivessel Intervention in STEMI Targets, Guidance, Data Review, and Future Directions

Presenter: Thomas Engstroem, Barry D. Rutherford, Shamir R. Mehta

October 11, 2015

Presentation TCT 2015

Keynote Lecture: What It Was Like to Discover the Stent: A Personal Journey

Presenter: Marvin L. Woodall, Julio C. Palmaz

October 11, 2015

News Daily News

ADAPT-DES Substudy: Practice Changes May Decrease Already Low Stent Thrombosis Rates Even Further

Yael L. Maxwell

October 09, 2015

News Daily News

Revascularization May Benefit Stable CAD Patients With Unclassifiable Appropriateness Scores

Todd Neale

October 08, 2015

News Daily News

Cap, Patient Shield Provide Substantial Reductions in Operator Radiation Exposure

Yael L. Maxwell

October 07, 2015

News Daily News

Study Hints That Many ICU Admissions for Acute MI Patients May Be Unnecessary

Todd Neale

September 28, 2015

News Industry News

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

September 28, 2015

News Daily News

Upstream Bivalirudin Best in NSTE-ACS Patients With Planned Invasive Strategy

L.A. McKeown

September 21, 2015

News Daily News

Cerebral Embolization Greater When Valvuloplasty Not Done Before TAVR

Todd Neale

September 21, 2015

Advertisement

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Ticagrelor (PEGASUS Trial)!

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Clopidogrel and Prasugrel (DAPT Trial)!

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Prasugrel for Primary PCI Is Simplest and Best!

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Oral or Crushed Ticagrelor for All!

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? The Mechanism and Data Support Cangrelor!

Case Resolution: How Did We Treat Our STEMI Patient With Multivessel Disease (and What Were the Long-term Outcomes)?

Case Introduction: A STEMI Patient With Multivessel Disease

Impact of CTO Revascularization After Primary PCI for AMI: Is This Where the Benefit Lies?

Nonculprit Lesions in STEMI Patients With Multivessel Disease: Is the Issue Ischemia or Vulnerable Plaque?

Should FFR Be Used Routinely in STEMI Patients With Multivessel Disease, and Is It Reliable During the Index and/or Staged Procedures?

Updated Meta-analysis of Culprit Only vs Complete Revascularization in STEMI: Are We Impacting Death and Reinfarction or Repeat Revascularization Only?

Introduction: A Critical Appraisal of Culprit Only vs Multivessel Intervention in STEMI Targets, Guidance, Data Review, and Future Directions

Keynote Lecture: What It Was Like to Discover the Stent: A Personal Journey

ADAPT-DES Substudy: Practice Changes May Decrease Already Low Stent Thrombosis Rates Even Further

Revascularization May Benefit Stable CAD Patients With Unclassifiable Appropriateness Scores

Cap, Patient Shield Provide Substantial Reductions in Operator Radiation Exposure

Study Hints That Many ICU Admissions for Acute MI Patients May Be Unnecessary

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

Upstream Bivalirudin Best in NSTE-ACS Patients With Planned Invasive Strategy

Cerebral Embolization Greater When Valvuloplasty Not Done Before TAVR

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content